Key result
Candidate vaccine strain A-EA-2007 demonstrated >90% in-vitro cross-protection against circulating serotype A FMDVs, compared to only 5.4-46.4% cross-reactivity for existing vaccine strains.
The A-EA-2007 vaccine strain demonstrates broad cross-neutralisation against recently circulating serotype A FMDVs, making it a suitable candidate for regional control programmes.
No takes yet. Share an insight, caveat, or question.
Supports preclinical advancement of A-EA-2007; leaves open in vivo efficacy and field performance in livestock.
Bari et al. (2014) studied Foot-and-mouth disease (n=56). Candidate vaccine strains (e.g., A-EA-2007) vs. Existing vaccine strains was evaluated on In-vitro cross-protection / cross-reactivity. Candidate vaccine strain A-EA-2007 demonstrated >90% in-vitro cross-protection against circulating serotype A FMDVs, compared to only 5.4-46.4% cross-reactivity for existing vaccine strains.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: